Free cookie consent management tool by TermsFeed Policy Generator

Ensayos Clínicos

A RANDOMIZED DOUBLE-BLIND CONTROLLED PHASE 3 STUDY OF CABOZANTINIB IN COMBINATION WITH NOVOLUMAB AND IPLIMUMAB VERSUS NIVOLUMBAB AND IPLIMUMAB IN SUBJECTS WITH PREVIOSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK

Ficha Técnica

Investigador Principal

MARIA JOSE MENDEZ VIDAL

Promotor

EXELIXIS INC

ESTADO

ACTIVO

DEPARTAMENTO

Oncología Médica

Código EudraCT: 2018-004567-31

Número protocolo: XL184-313

Fecha Inicio: 2019-10-16

Fecha Fin: 2023-05-31